Neuren Pharmaceuticals with Proactive at ASX Small and Mid-Cap Conference

Neuren Pharmaceuticals CEO Jon Pilcher speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022. Neuren Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neurological disorders that emerge in childhood. The company has two drugs in clinical development for multiple serious neurological diseases for which there are currently no approved drug therapies.
#NeurenPharmaceuticals #drugtherapy #neurologicaldisorders #asx #proactiveaustralia

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews